115 related articles for article (PubMed ID: 16809805)
1. Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers.
Li SX; Pequignot E; Panebianco D; Lupinacci P; Majumdar A; Rosen L; Ahmed T; Royalty JE; Rushmore TH; Murphy MG; Petty KJ
J Clin Pharmacol; 2006 Jul; 46(7):792-801. PubMed ID: 16809805
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects.
Dimmitt DC; Cramer MB; Keung A; Arumugham T; Weir SJ
Cancer Chemother Pharmacol; 1999; 43(2):126-32. PubMed ID: 9923817
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
[TBL] [Abstract][Full Text] [Related]
4. Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate.
Dimmitt DC; Hunt TL; Spalitto AJ; Cramer MB; Shah AK; Arumugham T; Hahne W
Ann Pharmacother; 1998 Jan; 32(1):39-44. PubMed ID: 9475818
[TBL] [Abstract][Full Text] [Related]
5. Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1.
Dimmitt DC; Choo YS; Martin LA; Arumugham T; Hahne WF; Weir SJ
Biopharm Drug Dispos; 1999 Jan; 20(1):29-39. PubMed ID: 10086835
[TBL] [Abstract][Full Text] [Related]
6. Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
Adams LM; Johnson B; Zhang K; Yue L; Kirby LC; Lebowitz P; Stoltz R
Support Care Cancer; 2009 Sep; 17(9):1187-93. PubMed ID: 19205754
[TBL] [Abstract][Full Text] [Related]
7. Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2.
Dimmitt DC; Choo YS; Martin LA; Arumugham T; Hahne WF; Weir SJ
Biopharm Drug Dispos; 1999 Jan; 20(1):41-8. PubMed ID: 10086836
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction.
Stubbs K; Martin LA; Dimmitt DC; Pready N; Hahne WF
J Clin Pharmacol; 1997 Oct; 37(10):926-36. PubMed ID: 9505984
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women.
Keung AC; Landriault H; Lefebvre M; Gossard D; Dempsey EE; Juneau M; Dimmitt D; Castles M; Roberts L; Spenard J
Biopharm Drug Dispos; 1997 May; 18(4):361-9. PubMed ID: 9158883
[TBL] [Abstract][Full Text] [Related]
10. Multiple-dose, placebo-controlled, phase I study of oral dolasetron.
Hunt TL; Cramer M; Christy-Bittel J; Shah AK; Meyerson LJ; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):253-60. PubMed ID: 8820469
[TBL] [Abstract][Full Text] [Related]
11. Single-dose, placebo-controlled, phase I study of oral dolasetron.
Dixon RM; Cramer M; Shah AK; Whitmore J; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):245-52. PubMed ID: 8820468
[TBL] [Abstract][Full Text] [Related]
12. Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats.
Herndon AK; Quimby JM; Sieberg LG; Davis L; Caress AL; Ligas S; Hansen RJ; Wittenburg LA; Gustafson DL
J Feline Med Surg; 2018 Aug; 20(8):721-727. PubMed ID: 28905667
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy.
Lippert CL; Dimmitt DC; Martin L; Cramer MB; Plezia P; Hahne WF
Am J Ther; 1999 May; 6(3):129-35. PubMed ID: 10423655
[TBL] [Abstract][Full Text] [Related]
14. Effect of aprepitant on the pharmacokinetics of intravenous midazolam.
Majumdar AK; Yan KX; Selverian DV; Barlas S; Constanzer M; Dru J; McCrea JB; Ahmed T; Frick GS; Kraft WK; Petty KJ; Greenberg HE
J Clin Pharmacol; 2007 Jun; 47(6):744-50. PubMed ID: 17463213
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ; Yanofsky R; Pritchard S; Leclerc JM; Howard DR; Perrotta M; Keays S; Pyesmany A; Dempsey E; Pratt CB
J Pediatr Hematol Oncol; 1999; 21(4):274-83. PubMed ID: 10445889
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children.
Lerman J; Sims C; Sikich N; Gow R; Chin C; Dempsey E; Howard DR; Keung AC
Clin Pharmacol Ther; 1996 Nov; 60(5):485-92. PubMed ID: 8941021
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
Sanwald P; David M; Dow J
Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
[TBL] [Abstract][Full Text] [Related]
19. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
20. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ; Lau R; Ingram LC; Wiernikowski JT; Grant R; Howard DR; Perrotta M; Barr R; Dempsey E; Greenberg ML; Leclerc JM
Med Pediatr Oncol; 1999 Aug; 33(2):99-105. PubMed ID: 10398184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
